Alnylam Pharmaceuticals
Business Account Executive: Onpattro, Upstate, NY (Finance)
Rochester, Buffalo, Syracuse, Utica, and Binghamton, NY)
Alnylam is the industry leader in the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to address the unmet needs of patients with debilitating diseases. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipeline of investigational RNAi therapeutic medicines, including five programs in late-stage development. Alnylam currently has two commercial RNAi therapeutic products. The first product is approved in the U.S., EU, Canada, Japan, and Switzerland for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults and the second product is approved in the U.S. for the treatment of adults with acute hepatic porphyria (AHP). Alnylam also has a deep pipeline of investigational medicines, including five product candidates that are in late-stage development. Headquartered in Cambridge, Mass., Alnylam employs over 1,300 people in 18 countries and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe's Top Places to Work five years in a row (2015-2019), a Great Place to Work in the U.K. and Switzerland in 2019 and Science Magazine's #1 Top Employer in 2019. Please visit www.alnylam.com for more information
We are looking for experienced Business Account Executives (BAEs) with rare disease experience to promote ONPATTRO (patisiran) in the U.S. ONPATTRO was approved in August 2018 by the FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults.
hATTR amyloidosis is a little-known condition in the United States and patients often spend years undiagnosed and misdiagnosed. There is an amazing opportunity to educate and enhance the market's knowledge of hATTR amyloidosis.
The hATTR amyloidosis BAE (ON BAE) will be principally responsible for driving physician and patient identification, disease awareness, overall market development, and brand awareness within their ascribed territory. The BAE will be responsible for achieving territory targets and other business objectives through account and customer strategies, while also partnering & collaborating very closely with internal and external stakeholders to effectively manage all aspects of the regional business. The achievement of targets will be based in Alnylam values: our commitment to people, sense of urgency, passion for excellence, innovation & discovery, open culture as well as our unwavering commitment to integrity.
The position reports into the ONPATTRO (ON) Regional Business Director.
Summary of Key Responsibilities:
Qualifications:
Expectations:
Clear Alignment with Alnylam Core Values
Alnylam Pharmaceuticals is an EEO employer committed to an exciting, diverse, and enriching work environment. #LI- BS1